Status:
UNKNOWN
Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Susceptibility, Genetic
Chemotherapy Effect
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
We plan to carry out a prospective, randomized, open phase III clinical trial which sponsored by the Tianjin Medical University Cancer Hospital and Institute. The primary aim is to evaluate pCR of DT ...
Detailed Description
This is a prospective, randomized, open phase III clinical trial which will be sponsored by the Tianjin Medical University Cancer Hospital and Institute. The primary aim is to evaluate pCR of Pegylate...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Compliance with test procedures and good compliance
- Females, Age more than 18 years of age, less than 70 years old
- The ECOG score is 0-1
- Primary invasive cancer, T2-4bN0-2M0 breast cancers
- Neoadjuvant chemotherapy with standard 6 courses should be completed
- Patients must undergo standard breast cancer surgery after neoadjuvant chemotherapy
- Luminal B, Her2 negative patients
- No other malignant tumors occurred at the same time
- adequate liver and kidney function
Exclusion
- Any metastasis
- Suffered other maligant tumors
- Participate in other trials
- Accompanied with severe systemic disease and / or uncontrollable infection
- Pregnant and lactating women
- Dysfunction of liver and kidney
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03359694
Start Date
December 1 2017
End Date
October 1 2022
Last Update
December 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jin Zhang
Tianjin, China, 300000